Elena María Vida Navas Alberto Martínez Lorca Aintzane Sancho Gutiérrez Lucia Sanz Gómez Teresa Navarro Martínez Enrique Grande Pulido Alfredo Carrato Mena Pablo Gajate Borau
10.3389/fendo.2021.676973
Front Endocrinol (Lausanne)
2021 Apr 15;12:676973.
lu-dotatate case report neuroendocrine neoplasms neuroendocrine tumors peptide receptor radionuclide therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/33935979/
Bone Neoplasms / radiotherapy Neuroendocrine Tumors / radiotherapy Octreotide / analogs & derivatives Organometallic Compounds / therapeutic use Radiopharmaceuticals / therapeutic use Rectal Neoplasms / radiotherapy
Bone Neoplasms / radiotherapy Neuroendocrine Tumors / radiotherapy Octreotide / analogs & derivatives Organometallic Compounds / therapeutic use Radiopharmaceuticals / therapeutic use Rectal Neoplasms / radiotherapy Case Reports Adult Antineoplastic Agents / therapeutic use Bone Neoplasms / diagnostic imaging Bone Neoplasms / drug therapy Bone Neoplasms / secondary Everolimus / therapeutic use Humans Magnetic Resonance Imaging Male Neuroendocrine Tumors / diagnostic imaging Neuroendocrine Tumors / drug therapy Neuroendocrine Tumors / secondary Octreotide / therapeutic use Rectal Neoplasms / diagnostic imaging Rectal Neoplasms / drug therapy Rectal Neoplasms / pathology Retreatment Sunitinib / therapeutic use Tomography, X-Ray Computed Antineoplastic Agents Organometallic Compounds Radiopharmaceuticals Everolimus lutetium Lu 177 dotatate Octreotide Sunitinib
PMC8082310
33935979
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
2021